

## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

### **Listing of Claims**


1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain having a sequence of amino acids CX<sup>IV</sup><sub>1</sub>X<sup>IV</sup><sub>2</sub>X<sup>IV</sup><sub>3</sub>X<sup>IV</sup><sub>4</sub>X<sup>IV</sup><sub>5</sub>X<sup>IV</sup><sub>6</sub>X<sup>IV</sup><sub>7</sub>X<sup>IV</sup><sub>8</sub>X<sup>IV</sup><sub>9</sub>X<sup>IV</sup><sub>10</sub>C approximately 17 to 40 amino acids in length that binds to a G-CSFR, wherein said and contains a sequence of amino acids is selected from the group consisting of GGGLLDICEELKLQECARRCN (SEQ ID NO: 209); GRTGGLLDICEELKLQECARRCN (SEQ ID NO: 210); LGIEGRTGGGLLDICEELKLQECARRCN (SEQ ID NO: 211); LLDICEELKLQEAARRCN (SEQ ID NO: 212); LLDIAELKLQECARRCN (SEQ ID NO: 464); KLLDICEELKLQEAARRCN (SEQ ID NO: 213); and LLDICEELKLQECARRAN (SEQ ID NO: 343), and wherein each amino acid is indicated by standard one-letter abbreviation.

163. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICEELKLQECARRCN (SEQ ID NO: 209).

164. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICEELKLQECARRCN (SEQ ID NO: 210).

165. (Canceled) The compound of claim 162, comprising a dimer having the structure of formula (VIII)



wherein R<sup>+</sup> and R<sup>2</sup> are independently selected from the sequences of amino acids of claim 1; formula (V); βA is a β-alanine residue; n1, n2, n3, n4, x and y are independently zero or one with the proviso that the sum of x and y is either one or two; and Lk is a terminal linking moiety selected from the group consisting of a disulfide bond, a carbonyl moiety, a C1-12 linking moiety optionally terminated with one or two NH linkages and optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue or a lysine amide.

166. (Previously presented) The compound of claim 162, containing a disulfide bond.

167. (Currently amended) The compound of claim claims-162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.

168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.

169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.

170. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of any claim-162, in combination with a pharmaceutically acceptable carrier.

171. (Withdrawn) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of claim 162.

172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.

173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.

174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.

175. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICEELKLQECARRCN (SEQ ID NO: 211).

176. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDICEELKLQEAARRCN (SEQ ID NO: 212).

177. (Currently amended) Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDIAELKLQECARRCN (SEQ ID NO: 464), KLLDICEELKLQEAARRCN (SEQ ID NO: 213).

178. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343).